Drugs /

pegaspargase

Back to Drugs List

Overview

Generic Name(s):
pegaspargase
Trade Name(s):
Oncaspar
NCI Definition [1]:
A complex of polyethylene glycol conjugated with L-asparaginase. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle. The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)

Clinical Trials

View Clinical Trials for pegaspargase

Pegaspargase has been investigated in 23 clinical trials, of which 23 are open and 0 are closed. Of the trials investigating pegaspargase, 6 are phase 1 (6 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), 9 are phase 3 (9 open), and 1 is no phase specified (1 open).

BCR-ABL1 Fusion, t(9;22)(q34;q11), and Hypodiploidy are the most frequent biomarker inclusion criteria for pegaspargase clinical trials.

B-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, and mixed phenotype acute leukemia are the most common diseases being investigated in pegaspargase clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pegaspargase
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pegaspargase and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Oncaspar, pegaspargase (substance), (monomethoxypolyethylene glycol succinimidyl)74-l-asparaginase, 3777, peg-l-asparaginase (enzon - kyowa hakko), polyethylene glycol asparaginase, peg-asparaginase, peg-asp, l-asparaginase with polyethylene glycol, 644954, pegaspargase (product), putative l-asparaginase precursor, asparaginase polyethylene glycol, polyethyleneglycol-asparaginase, polyethylene glycol-l-asparaginase, (monomethoxypolyethylene glycol succinimidyl)74-l-asparaginase, 4056, pegla, pegaspargase [chemical/ingredient], peg-l-asparaginase, polyethylene glycol l-asparaginase, 624239, l-asparagine amidohydrolase, pegaspargase, polyethylene glycol-l-asparaginase, peg-asparaginase, asparaginase macrogol, peg-l-asparaginase(k-h), l-asparaginase with polyethylene glycol, peg-l-asparaginase, pegaspargase
Drug Categories [2]:
Protein synthesis inhibitors
NCIT ID [1]:
C1200
SNOMED ID [1]:
C-78279

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.